A seminal 2024 study demonstrated the efficacy of a subunit vaccine containing GapA, CrmA, and four early-expressed VlhAs, which, when paired with a CpG ODN adjuvant, significantly reduced tracheal pathology and MG recovery in challenged chickens (Miller et al., 2024). The gene discussed is CRMA; the disease is myasthenia gravis.